Could a 2-Month TB cure replace 6 months of pills for kids?

NCT ID NCT06253715

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This study tests whether a 2-month combination of four drugs can cure drug-susceptible tuberculosis in children under 10 as safely and effectively as the standard 4- to 6-month regimen. Researchers will enroll 860 children, including those with HIV, to compare the shorter treatment to the usual one. The goal is to make TB treatment easier for children and their families.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
isoniazid, rifapentine, pyrazinamide, moxifloxacin
What this could lead to
If successful, this could offer a shorter, easier-to-tolerate treatment for children with TB, reducing side effects and caregiver burden.
What could go wrong
This is a large phase 3 trial, but the shorter regimen may prove less effective or cause more side effects than the standard treatment. Results are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Africa Health Research Institute (AHRI)

    RECRUITING

    Durban, South Africa

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Arthur Davison Children's Hospital

    RECRUITING

    Ndola, Zambia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dr. D.Y. Patil Medical College, Hospital and Research Center

    RECRUITING

    Pune, India

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Faculty of Medicine, Universitas Padjadjaran

    RECRUITING

    Bandung, Indonesia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Harare Health and Research Consortium (HHRC)

    RECRUITING

    Harare, Zimbabwe

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Indian Council of Medical Research - National Institute for Research in Tuberculosis

    RECRUITING

    Chennai, India

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Instituto Nacional de Saúde (INS)

    RECRUITING

    Maputo, Mozambique

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • MU-JHU Care Ltd

    RECRUITING

    Kampala, Uganda

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Zambia, School of Medicine

    RECRUITING

    Lusaka, Zambia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.